Code History FY 2026 - No Change, effective from 10/1/2025 through 9/30/2026 FY 2025 - No Change, effective from 10/1/2024 through 9/30/2025 FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024 FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023 FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022 FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021 FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020 FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019 FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018 FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017 FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
Nerve and tissue repair: Research shows GHK-Cu promotes neurite outgrowth and supports repair of nerve tissue, making it a candidate peptide for post-surgical or neuropathy-adjacent protocols
However, despite these promising advantages, clinical research is still limited, and FDA approval has not been granted
The persistent effects mean daily dosing is likely unnecessary
At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity
